EGFR and benign prostatic hyperplasia: The CYP19/estrogen/GPER pathway modulates EGFR/ERK and HIF-1α/TGF-β1 signaling, all of which have key roles in the proliferation and fibrogenesis of prostatic stromal cells in patients with accelerated clinical progression of BPH (Fig. 7).